Ranbaxy Receives US Approval for Manufacturing and Marketing Ramipiril

India’s Ranbaxy Laboratories has received the nod of U.S. Food and Drug Administration to manufacture and market ramipril capsules.

Ramipril is used in the treatment of cardiovalscular diseases.

ACE Inhibitor
Treatment with an ACE inhibitor decreases preload and afterload by blunting the exaggerated peripheral compensatory response. ACE inhibitors should be considered first-line therapy for Heart Failure.

Ramipril is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys resulting in a stroke, heart failure, or kidney failure. Hypertension may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.

Ramipril works by blocking an enzyme in the body that is necessary to produce a substance that causes blood vessels to tighten. As a result, the blood vessels relax. This lowers blood pressure and increases the supply of blood and oxygen to the heart.

Ramipril is also used in some patients after a heart attack. After a heart attack, some of the heart muscle is damaged and weakened. The heart muscle may continue to weaken as time goes by. This makes it more difficult for the heart to pump blood. Ramipril may be started within the first few days after a heart attack to increase survival rate.

In addition, ramipril is used to lessen the chance of heart attacks, strokes, or death in people who are 55 years of age or older and have serious heart disease.

Latest in Cardiovascular Care Unveiled
American cardiologists convene in Chicago this weekend for the world's largest confab on heart disease, where results of major clinical trials that could influence medical practice will be unveiled.

Source-Medindia
GPL